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Checkmate to Bioethics?  
The Case of covid-19
Bioethics, as the first cousin of philosophy, 
suffers from what philosopher Hegel told us 
during his lifetime, “When philosophy paints 
lights and shadows, an aspect of life has grown 
old, and cannot be rejuvenated, but only under-
stood. Minerva’s owl takes flight only during 
sundown” (1, p.36). The problem is how to fight 
an invisible opponent. What to do when your op-
ponent enters your body and kills you from the 
inside? This pandemic has taken away out trust 
in the “Other,” even if they are our parents or 
children, since it turns a simple act of love —a 
kiss or a hug— into a deadly weapon. No one, not 
the richest nor the poorest country, was prepared 
for this. The covid-19 pandemic has put the 
world in check and proposes a new planetary or-
der. Bioethics must take its most reflective streak, 
understand the phenomenon, and draw lessons 
from this heartbreaking experience so that we do 
not make the same mistakes again that are cost-
ing us so many bitter tears and deaths.
I will present below some points that may 
help us to continue the debate and possi-
bly reach agreements on how to advance in a 
post-covid-19 world:
 ◾ The controversy between individual liber-
ties and the common good, or in bioethical 
terms, between citizens’ autonomy and the 
welfare of society. This controversy is not 
new since Kant himself wondered how the 
idea of authority could be reconciled with the 
postulate that individuals are free to set their 
goals and purposes, according to their judg-
ment (2). For philosopher Victoria Camps, 
“between individual freedom and the com-
mon good there should be no contradiction if 
an attitude of responsibility prevails.” Camps 
appeals to the commitment of each citizen to 
a common good, which is, in this scenario, to 
stop the infection and avoid the collapse of the 
health care system. Most citizens have shown 
their commitment and conviction upon un-
derstanding that the limitation of freedom 
imposed by “a mandatory quarantine” had to 
be accepted as the best alternative to fight this 
disease. We must also recognize that this im-
position has been welcomed based on dread 
and fear, rather than on a rational act, while a 
feeling of compassion has elicited a support-
ive, selfless response from citizens (3).
 ◾ A race to cure the disease. Does the end 
justify the means? The ideal would be con-
ducting multinational and public research to, 
firstly, understand the disease and formulate 
appropriate management interventions and 
practices and, secondly, evaluate the safety 
and efficacy of any proposed diagnostic tests, 
treatments, vaccines, and management strat-
egies. This ideal has many difficulties: 1) the 
competition among governments, laborato-
ries, and scientists to produce the first vac-
cine; 2) patent ownership and exploitation 
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by whoever makes the best offer, and 3) the 
relaxation and omission of some phases of 
clinical research or ethical criteria (e.g., in-
formed consent, review by a Research Ethics 
Committee, among others). 
 ◾ The doubtful safety and effectiveness of a 
vaccine developed in such a short period. 
For example, the experimental mrna-1273 
vaccine was developed by scientists from the 
U.S. National Institute of Allergy and Infec-
tious Diseases (niaid) in cooperation with the 
biotechnology company Moderna. It began to 
be tested on 45 healthy volunteers between 18 
and 55 years of age, even though there is no 
safety data on the vaccine in preclinical trials 
(the fda authorized the performance of ani-
mal testing for the vaccine at the same time as 
phase I trials with healthy volunteers). These 
trials are critical as they provide evidence 
that vaccinated animals did not experience 
severe side effects and developed immunity to 
the disease concerned. Similarly, consent for 
the phase I vaccine trial is not publicly avail-
able; it is unclear whether healthy individuals 
were informed of the potential risks of receiv-
ing mrna-1273 doses and from which sources 
such risk information was obtained (4).
On the other hand, the safety and efficacy of 
covid-19 drugs are being tested on humans. For 
example, we have heard from President Trump 
himself that chloroquine and hydroxychloro-
quine—both approved by the fda to treat ma-
laria and certain autoimmune diseases—could 
be effective treatments for covid-19. However, 
in the few studies where testing was performed, 
the number of participants was small, and they 
were not randomized into a treatment group and 
a control group (placebo). The results of their 
therapeutic effectiveness are not promising, in 
addition to the side effects of taking hydroxy-
chloroquine such as nausea, diarrhea, skin rash, 
skin pigmentation (such as darkening or dark 
spots), changes in hair, and muscular weakness. 
Hydroxychloroquine can rarely cause anything 
from anemia to visual problems or vision loss, 
and there is also a real danger of shortage for 
patients with lupus and other autoimmune dis-
eases who have been using this approved medi-
cation for years.
At this rate, it is possible that the agencies 
in charge of approving drugs, either the fda or 
Invima (in Colombia), will approve a covid-19 
vaccine or treatment based on the efficacy data 
of phase ii clinical trials instead of phase iii trials 
with more participants and/or studies other than 
randomized clinical trials, with questionable ev-
idence and little safety and efficacy. We would 
not want to repeat past mistakes such as thalid-
omide or recently Avastin (whose generic name 
is bevacizumab), which was approved by the fda 
for use in combination with Taxol (paclitaxel) in 
February 2008 to treat patients diagnosed with 
metastatic her2-negative breast cancer (not hav-
ing received chemotherapy yet). However, such 
approval was revoked shortly after because sub-
sequent data established that its harm to patients 
outweighed its benefits.
 ◾ Distribution of resources. Who lives and 
who dies? The question brought about by 
the covid-19 pandemic reminds me of Ger-
man philosopher and psychiatrist K. Japers 
and his concept of limit situation (Grenzsit-
uation), “We are always in situations. Situa-
tions change, opportunities arise. If they are 
lost they never return. I myself can work to 
change the situation. But there are situations 
which remain essentially the same even if 
their momentary aspect changes and their 
shattering force is obscured: I must die, I 
must suffer, I must struggle, I am subject to 
chance, I involve myself inexorably in guilt. 
We call these fundamental situations of 
our existence limit situations. That is to say, 
they are situations which we cannot evade 
or change. Along with wonder and doubt, 
awareness of these ultimate situations is the 
most profound source of philosophy” (5). The 
pandemic is leading us into making decisions 
in extreme situations.
Spain, one of the covid-19 hardest-hit coun-
tries, has 235,777 cases and 28,700 deaths as of 
today (05/24). One of the reasons why there have 
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been so many deaths is the collapse of their health 
care system, especially intensive care units (icus). 
According to data from the 2018 Spanish Minis-
try of Health, there are 4,267 icu beds in public 
and private hospitals, although the total number 
of beds has tripled in some communities during 
the epidemic. Since April 28, the accumulated 
percentage of coronavirus patients admitted to 
icus has been reported to be 9.2 % (11,472) of the 
124,757 people hospitalized. How are resources 
to be distributed in the face of this panorama? 
How can ethics or bioethics stand this reality? In 
many hospitals, patients died without receiving 
any treatment. Latin America had a small advan-
tage in that the pandemic came a few weeks later, 
which enabled some (not all) countries to take 
some far-reaching measures, along with hygiene 
and social distancing protocols, and make every 
effort to avoid maxing out hospitals and clinics. 
In addition to curbing the exponential level of 
contagion, quarantine prevents patients from us-
ing the emergency services at the same time and 
distributes them over time.  
This situation allowed implementing some 
recommendations made by multiple agen-
cies, including the World Health Organiza-
tion (who), about decision-making with scarce 
resources (such as ventilators or icu beds) to 
meet all the needs of the population during the 
covid-19 pandemic. Given that we cannot do 
everything that must be done, what is the most 
ethical way to proceed? Acting responsibly re-
quires the establishment of prioritization cri-
teria when making decisions. The who made 
four recommendations: 1) establish transparent 
prioritization criteria: the existence of transpar-
ent and publicly accessible criteria strengthens 
the people’s trust in health authorities, which 
is key to their support, and takes this weight 
off of intensivists; 2) save the highest number of 
lives: this involves prioritizing those who are in 
the best clinical condition to survive treatment 
over those who will hardly recover even with 
treatment. The latter does not imply abandoning 
patients; they should always be given the neces-
sary palliative care in the absence of treatment; 
3) prioritize health workers: doctors, nurses, 
therapists, and others risk their lives to save the 
lives of others. Therefore, prioritizing their care 
satisfies a criterion of justice and allows saving 
the highest number of lives due to their central 
role in the care of others, and 4) treat everyone 
fairly: every patient (with covid-19 or another 
illness) should be treated equally. Following the 
principles of justice and equity, it is essential to 
ensure that there is neither differentiated treat-
ment according to privilege nor discrimination 
due to age, ethnicity, religion, sexual orientation, 
socioeconomic status, ideology, or other criteria 
unrelated to these recommendations (6).
 ◾ Our health professionals are heroes, but 
not martyrs. According to the Royal Spanish 
Academy, the word martyr has three mean-
ings: 1) a person who is killed because of their 
religion; 2) a person who is killed or suffers 
significantly because of their beliefs or con-
victions, and 3) a person who makes sacrifices 
to fulfill their obligations. Let us not turn our 
health professionals into martyrs. In several 
interviews, health professionals state that, 
besides being applauded from balconies, they 
urgently require personal protection equip-
ment and supplies to treat those in need ef-
ficiently. Moreover, this claim is neither false 
nor unfounded fear because many health 
workers at a considerable number of hospitals 
in the country barely have essential resources, 
which contrasts with the growing demand for 
medical services created by the pandemic (7).
Despite everything, the novel coronavirus 
has left us in check, but not mate yet. Although 
the king is threatened, this situation can be 
changed using a legal move because the human 
being has an extraordinary capacity called resil-
ience to overcome critical moments and adapt 
after experiencing some unusual and unexpect-
ed circumstances. It also means returning to 
normal. Right now, we are already thinking in 
post-coronavirus terms: we are capable of heal-
ing the deep scars left by the pandemic to think 
about and plan a better future. We are about to 
take the crown away from the king.
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In the name of the editorial board of Revista 
Latinoamericana de Bioética and my own, we de-
dicate this issue to the heroes of this pandemic, 
the health professionals (doctors, nurses, para-
medics, to name just a few) who have risked their 
lives for the most vulnerable and feeble, those 
who have suffered the agony of this utterly heart-
less coronavirus disease.
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Note: We inform our readers and collaborators that Revista Latinoamericana de Bioética will adopt a different 
numbering system from now on. Until last year, the journal used a three-factor numbering system containing 
a volume indicator that coincided with the last two numbers of the current year, a serial indicator of the total 
number of issues published by the journal, and, finally, a frequency indicator of whether the number was pub-
lished in January–June (1) or July–December (2). Therefore, the last two issues were designated 19-36-1, indicating 
that it was the 36th issue of the journal published in the first half of 2019, and 19-37-2, indicating that it was the 
37th issue of the journal published in the second half of 2019. However, this numbering was hard to follow as it 
is contrary to most journals’ usual systems and it did not match the one assigned to our issues by international 
indexation databases. Besides, the fact that the serial indicator followed the total number of issues made it 
seem as if the first referred to the volume, wich led some readers and contributors to believe that, for example, 
the second number of volume 36 and the first number of volume 37 in 2019 were lost or forgotten in our publi-
cation history.
From now on, Revista Latinoamericana de Bioética will adopt a much more consistent and standardized num-
bering system, consisting only of a volume indicator referring to the current publishing year and a frequency 
indicator that determines whether the number was published in January–June (1) or July–December (2). This 
numbering system not only matches the one that has historically been assigned to us by indexation databases, 
but also makes our publication frequency clearer and more familiar to our very dear community of readers and 
contributors.
 ■ F. A. Garzón Díaz10
